Key Details
Price
$142.35PE Ratio
12.86Annual ROE
8.24%Beta
0.57Events Calendar
Next earnings date:
Feb 13, 2025Recent quarterly earnings:
Oct 30, 2024Recent annual earnings:
Feb 13, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Jan 18, 2001Analyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
We have put together a list of the 12 Best S&P 500 Stocks to Invest in Based on Analyst Recommendations. In this article, we will examine how Biogen Inc. (NASDAQ:BIIB) compares to other S&P 500 stocks. The year 2024 was significant for the overall market index, which saw an increase of 23.31%.
On January 31, 2025, Eisai Co., Ltd. from Tokyo and Biogen Inc. from Cambridge, Massachusetts, shared an update regarding the regulatory review of their Marketing Authorization Application for lecanemab. This treatment is aimed at early Alzheimer's disease, specifically for mild cognitive impairment and mild Alzheimer's. The announcement highlights their progress in seeking approval in the European Union.
Biogen (BIIB) has a strong track record of surprising with its earnings and currently has the right mix of factors that suggest it may exceed expectations in its upcoming quarterly report.
The FDA approved Biogen's Leqembi after reviewing simulation data from several studies. These studies indicate that taking the medication every four weeks helps to extend the benefits of biomarkers.
Giving maintenance doses every four weeks might be simpler for patients and their caregivers to keep up with Alzheimer's treatment. Even after clearing plaques, the disease continues to progress, but ongoing treatment with LEQEMBI can help slow this progression and extend the positive effects of the therapy. This information comes from Eisai Co., Ltd., based in Tokyo and Cambridge, Massachusetts.
Giving maintenance doses every four weeks might make it simpler for patients and their caregivers to keep up with treatment. Even after clearing plaques, Alzheimer's disease continues to progress, but ongoing treatment with LEQEMBI can help slow this progression and extend the positive effects of the therapy. This information comes from Eisai Co., Ltd., based in Tokyo and Cambridge, on January 26, 2025.
BIIB's regulatory documents are backed by recent data that indicate a higher dose of Spinraza enhances motor skills in infants with SMA.
The applications rely on information from the DEVOTE study, which shows that a higher dose of nusinersen could improve the treatment for SMA. This research highlights the promising effects of this new dosage. Overall, the findings suggest a positive step forward in SMA therapy.
Biogen Inc. (BIIB) participated in the 43rd Annual Healthcare Conference organized by J.P. Morgan. Here is a transcript of their presentation.
The CEO of Biogen stated that they anticipate revenue from new product launches will surpass their current sales by 2028, and they do not see the necessity to pursue more business development agreements.
FAQ
- What is the ticker symbol for Biogen?
- Does Biogen pay dividends?
- What sector is Biogen in?
- What industry is Biogen in?
- What country is Biogen based in?
- When did Biogen go public?
- Is Biogen in the S&P 500?
- Is Biogen in the NASDAQ 100?
- Is Biogen in the Dow Jones?
- When was Biogen's last earnings report?
- When does Biogen report earnings?
- Should I buy Biogen stock now?